Ved afslutningen af den gensidige anerkendelsesprocedure var der uoverensstemmelse mellem de forskellige EU- medlemsstater om sikkerheden ved etoricoxib i en dosis på 90 mg til den nye indikation.
At the end of the mutual recognition procedure, there was a discrepancy between different European Union (EU) Member States regarding the safety of etoricoxib at the 90mg dose in the new proposed indication.